Claims for Patent: 6,846,816

Summary for Patent: 6,846,816

Title:	Combinations of drugs for the treatment of neoplastic disorders
Abstract:	The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.
Inventor(s):	Borisy; Alexis (Boston, MA), Keith; Curtis (Boston, MA), Foley; Michael A. (Chestnut Hill, MA), Stockwell; Brent R. (Boston, MA)
Assignee:	CombinatoRx, Inc. (Boston, MA)
Application Number:	10/347,714
Patent Claims:	1. A method for treating a patient having cancer, said method comprising administering to said patient: a) a first compound having the formula (I): ##STR21## or a pharmaceutically acceptable salt thereof, wherein R.sub.2 is selected from the group consisting of: ##STR22## R.sub.10 is selected from the group consisting of: ##STR23## each of R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 is, independently, H, OH, F, OCF.sub.3, or OCH.sub.3 ; and W is selected from the group consisting of: ##STR24## and b) a second compound having the formula (II): ##STR25## or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N; each of R.sub.11 and R.sub.12 is, independently, H, Cl, Br, OH, OCH.sub.3, OCF.sub.3, NO.sub.2, and NH.sub.2 ; n is an integer between 2 and 6, inclusive; and each of R.sub.13 and R.sub.14 is, independently, selected from the group consisting of: ##STR26## wherein said first and second compounds are administered simultaneously or within 14 days of each other in amounts sufficient to treat said patient. 2. The method of claim 1, wherein said first and second compounds are administered within ten days of each other. 3. The method of claim 2, wherein said first and second compounds are administered within five days of each other. 4. The method of claim 3, wherein said first and second compounds are administered within twenty-four hours of each other. 5. The method of claim 1, said method further comprising administering to said patient one or more a chemotherapeutic agents selected from paclitaxel, docetaxel, tamoxifen, vinorelbine, gemcitabine, cisplatin, etoposide, topotecan, irinotecan, anastrozole, rituximab, trastuzumab, fludarabine, cyclophosphamide, gentuzumab, carboplatin, interferon, 5-FU, doxorubicin, and cytoxan. 6. The method of claim 5, wherein said first and second compounds are administered within ten days of each other. 7. The method of claim 6, wherein said first and second compounds are administered within five days of each other. 8. The method of claim 7, wherein said first and second compounds are administered within twenty-four hours of each other. 9. The method of claim 1, wherein said cancer is brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, or uterine cancer. 10. The method of claim 9, wherein said first and second compounds are administered within ten days of each other. 11. The method of claim 10, wherein said first and second compounds are administered within five days of each other. 12. The method of claim 11, wherein said first and second compounds are administered within twenty-four hours of each other. 13. A method for treating a patient having brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, or uterine cancer, said method comprising administering to said patient: a) a first compound having the formula (I): ##STR27## or a pharmaceutically acceptable salt thereof, wherein R.sub.2 is selected from the group consisting of: ##STR28## R.sub.10 is selected from the group consisting of: ##STR29## each of R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 is, independently, H, OH, F, OCF.sub.3, or OCH.sub.3 ; and W is selected from the group consisting of: ##STR30## and b) a second compound having the formula (II): ##STR31## or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N; each of R.sub.11 and R.sub.12 is, independently, H, Cl, Br, OH, OCH.sub.3, OCF.sub.3, NO.sub.2, and NH.sub.2 ; n is an integer between 2 and 6, inclusive; and each of R.sub.13 and R.sub.14 is, independently, selected from the group consisting of: ##STR32## wherein said first and second compounds are administered simultaneously or within 24 hours of each other in amounts sufficient to treat said patient.

Details for Patent 6,846,816

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2020-11-06
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2020-11-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2020-11-06